• menu
    Market Place Market Place
    Sourcing support Sourcing Support
    API / FDF
    Excipients
    Services
    Developments
    News
    Market Intel
    #Phispers
    #SpeakPharma
    #LearnMore

    NEWS

    DRUGS & DEVELOPMENTS

    MARKET INTEL by PharmaCompass

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.
    All News #Library
    Rare Diseases

    Novartis ianalumab receives BTD designation for Sjögren’s disease

    GLOBENEWSWIRE

    Cure SMA Welcomes FDA Approval of Itvisma for SMA

    PR NEWSWIRE

    Novartis Gets FDA Approval For Itvisma Gene Therapy In SMA

    PR NEWSWIRE

    Novartis Sues Az`s Alexion Over `Misleading` Ultomiris Marketing

    FIERCE PHARMA

    Analysis Group Explores HEOR Use in Rare Disease CGTs

    PR NEWSWIRE

    Novartis Fabhalta® improves hemoglobin in new PNH patients

    GLOBENEWSWIRE

    Novartis receives FDA accelerated approval for Vanrafia

    PR NEWSWIRE

    Novartis receives third FDA approval for oral Fabhalta

    GLOBENEWSWIRE

    Novartis Gene Therapy Benefits Kids with Rare Muscle Disorder

    PRESS RELEASE

    Novartis, Apellis roll out rival datasets in rare kidney disease

    FIERCE PHARMA

    Novartis quietly used a PRV to speed the approval of Rare blood disorder drug

    ENDPTS

    Novartis drug candidate scores interim win in rare kidney disease trial

    REUTERS

    Novartis to seek accelerated approval for oral complement inhibitor

    ENDPTS

    Former Novartis drug for ultra-rare disease gets speedy FDA review

    ENDPTS

    Novartis’ new rare disease drug Vijoice meant as `blank canvas`

    FIERCE PHARMA

    NHS England strikes deal on life-saving gene-therapy drug

    NHS

    Three Breast Cancer Drugs: FDA Warns of Rare but Serious Lung Inflammation

    RAPS

    Novartis licenses small molecule treatment for a genetic ultra-rare disease

    IN-PHARMATECHNOLOGY

    Novartis offloads a late-stage PI3K? rare disease program in a discount deal

    ENDPTS

    Novartis sells phase 3 rare disease drug to Pharming

    FIERCE BIOTECH

    AveXis receives FDA approval for Zolgensma®, the first and only gene therapy

    PR NEWSWIRE

    To be cost-effective, Biogen should slash Spinraza price

    ENDPTS

    One state plans to pay for $5 million priced rare disease drug

    BUSINESS INSIDER

    Novartis’ SMA gene-therapy, if priced at $2M, could be more cost-effective than Biogen’s Spinraza

    ENDPTS

    Teva successfully used a rare pediatric PRV to speed the approval for Ajovy

    RAPS

    Did Novartis get $150M worth of positive PhII cardio data from Akcea?

    ENDPTS

    Novartis says its top drug prospect is worth $4M-$5M for a once-and-done use

    ENDPTS

    AstraZeneca digs deeper into cancer with Innate stake

    REUTERS

    Novartis farms out rare disease drug to LifeMax Labs

    FIERCE BIOTECH

    Novartis quietly hands topical treatment for rare disease to LifeMax

    ENDPTS

    CSL Behring, Leader in Rare Diseases, Showcases Innovations Neuromuscular (NMM)

    PR NEWSWIRE

    How A Drugmaker Turned The Abortion Pill Into A Rare-Disease Profit Machine

    KHN

    EU green light for Novartis’ Rydapt

    PHARMA TIMES

    Novartis rare disease drug opens up new way to treat heart disease

    WASHINGTON

    Israel`s Gamida Cell raises $40 million for bone marrow trial

    REUTERS

    Novartis, Lilly Lead A $44M Round For Rare Disease Biotech Aeglea

    FIERCE BIOTECH

    Copyright © 2026 LePro PharmaCompass OPC Private Limited, All rights reserved.